TCGA-B6-A0RG-01A-11R-A056-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.530
- ESTROGEN_RESPONSE_LATE+0.510
- CHOLESTEROL_HOMEOSTASIS+0.350
- OXIDATIVE_PHOSPHORYLATION+0.300
- BILE_ACID_METABOLISM+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- TGF_BETA_SIGNALING+0.260
- FATTY_ACID_METABOLISM+0.240
- PEROXISOME+0.220
- XENOBIOTIC_METABOLISM+0.220
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.510
- INTERFERON_GAMMA_RESPONSE-0.380
- INFLAMMATORY_RESPONSE-0.330
- HEDGEHOG_SIGNALING-0.300
- IL6_JAK_STAT3_SIGNALING-0.280
- IL2_STAT5_SIGNALING-0.270
- INTERFERON_ALPHA_RESPONSE-0.260
- KRAS_SIGNALING_UP-0.260
- COMPLEMENT-0.240
- MYC_TARGETS_V2-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617914 | — | C | 0.736 |
| 2 | TCGA-A7-A13F-01A-11R-A12P-07 | — | B | 0.718 |
| 3 | SRR1313112 | — | B | 0.717 |
| 4 | SRR8518245 | — | F | 0.714 |
| 5 | SRR8518238 | — | C | 0.707 |
| 6 | BSR_19_0079_A1_S53 | — | B | 0.706 |
| 7 | SRR1313124 | — | B | 0.693 |
| 8 | TCGA-AR-A1AS-01A-11R-A12P-07 | — | B | 0.693 |
| 9 | TCGA-A2-A0EU-01A-22R-A056-07 | — | B | 0.692 |
| 10 | TCGA-BH-A0E1-01A-11R-A056-07 | — | B | 0.689 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.530 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.510 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |